Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Crucell member of the GAVI Alliance
Volgen
In mijn bedrijfsverslag werd aangegeven dat crucell nu met de 6 grootste vaccin producenten om tafel zit met o.a. de Bill Gates Foundation. Ik weet niet of iemand al dit had uitgezocht maar ik denk nu te weten onder welk platform dit is:www.ifpma.org/documents/NR5559/IFPMA_... Een pracht van een document (tis de groot om nu volledig uit te spitten, maar alle hulp welkom) uit de maand september 2006 dus zeer actueel waarin oa. ook de GAVI Alliance wordt besproken, met de volgende deelnemers: The Alliance’s partners include Berna Biotech (a Crucell company), GSK Biologicals, Merck & Co., Novartis Vaccines and Diagnostics (formerly Chiron Vaccines), sanofi pasteur, Wyeth and the IFPMA, plus industrialized and developing country governments, UNICEF, the WHO, the World Bank, charitable foundations and NGOs.www.gavialliance.org GAVI Partners: The Bill & Melinda Gates Foundation WHO UNICEF The World Bank Group Developing Country Governments Nongovernmental Organization Industrialized Country Governments Vaccine Industry-Industrialized Country Research and Technical Health Institutes Vaccine Industry-Developing Country Voorts is Crucell nog deelnemer in een taskforce genaamd: IFPMA Influenza Vaccine Supply International Task Forcewww.ifpma.org Conclusie: de overname van Berna heeft Crucell nog veel meer te bieden voor de toekomst. Doordat Crucell nu bij de grootste 6 hoort in de wereld praten ze dus aan de tafel met vooraanstaande instituten zoals WHO, Bill gates Foundation, UNICEF. Japie
Dit platform is belangrijk, blijkt wel gezien Quinvaxem en koppeling met Unicef en WHO. Voorts kan een Yellow Fever vaccin ook via dit platform in Q1/2006 snel een grote markt verkrijgen. Lijkt me ook dat een perc.6 technologie niet onbesproken zal blijven als Ronald Brus aan tafel zit met de 5 andere grootste vaccinproducenten van de wereld en de WHO en de Bill Gates Foundation. Japie
Goed gevonden, het begint erop te lijken dat we straks op moeten passen, dat we geen monopolypositie krijgen. De biotechindustrie gaat streven om een positie te krijgen binnen de innercirkel van Crucell. Alleen de hogestandaard bedrijven binnen de bioindustrie worden uitverkoren om een licentie te krijgen. Wel, alle gekheid op een stokje. PerC.6 wordt of eigenlijk is de cellijn van de 21ste eeuw. En de giganten gaan snel overstag. Weg met de eitjes, alleen op zondagmorgen niet, en welkom Crucell, Erik
Japies schreef:
In mijn bedrijfsverslag werd aangegeven dat crucell nu met de 6 grootste vaccin producenten om tafel zit met o.a. de Bill Gates Foundation.
Bassie is al eens een keer met die link gekomen: www.iex.nl/forum/topic.asp?forum=228&... Jouw opmerking in het bedrijfsverslag betreffen de de 6 grootste vond ik opmerkelijk maar ik dacht toen niet meteen aan GAVI. Ik denk dat je conclusie dat het dit platform is juist is.
Toch brengt dit artikel weinig los hier bij de meeste, maar bij mij wel!! Reken maar dat quinvaxem via dit platform nu zoveel omzet zal genereren via Unicef. En de volgende kan yellow fever zijn want die zit ook in het programma van GAVI. En dat is het eerstvolgende product in Q1/2007! Tuurlijk het huidige nieuws ie leuk, maar ik ben altijd bezig met het aanstaande nieuws :) Japie
En natuurlijk HIV, Malaria en TB.
Uit draadje Bill Gates steunt Crucell(d.d. 09092005): Statement by Bill Gates on the Launch of the International Finance Facility for Immunization SEATTLE – Bill Gates issued the following statement in response to today’s announcement that the governments of the U.K., France, Italy, Spain, and Sweden have pledged commitments to fund a $4 billion International Finance Facility for Immunization (IFFIm), which will support childhood vaccine programs through the Global Alliance for Vaccines and Immunization (GAVI): “The commitments announced today provide a major boost to GAVI’s work to ensure that all children—no matter where they are born—have access to lifesaving vaccines. I commend the U.K., France, Italy, Spain, and Sweden for their generosity, and Gordon Brown for his tireless work to make this announcement possible.” “Melinda and I believe that supporting GAVI is the best investment we’ve ever made. In just five years, GAVI has immunized tens of millions of children in the developing world, and saved hundreds of thousands of lives—that’s extraordinary progress. “The IFFIm will provide major new resources for GAVI to extend the reach of its programs. These funds are urgently needed—it’s unacceptable that each year, 27 million children go without immunizations that are taken for granted in rich countries. “The IFFIm is a bold and innovative approach to financing critical global health programs. The facility will make additional funds available more quickly to strengthen immunization systems, and make aid more stable and predictable over time. I hope that other donor governments will come on board to support the IFFIm.” The Bill & Melinda Gates Foundation works to promote greater equity in four areas: global health, education, public libraries, and support for at-risk families in Washington state and Oregon. The Seattle-based foundation joins local, national, and international partners to ensure that advances in these areas reach those who need them most. The foundation is led by Bill Gates's father, William H. Gates Sr., and Patty Stonesifer.www.iex.nl/forum/topic.asp?forum=228&... M.b.t. IFPMA: A specialized group within the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the Influenza Vaccine Supply international task force, has been created in February 2002 to assist business leaders in vaccine companies in making necessary decisions to ensure adequate capacity to produce and distribute influenza vaccine in interpandemic and pandemic years, as well as to assist health authorities policy makers in making decisions on vaccination recommendations and reimbursement, the level of vaccine use and vaccine delivery strategies. Member companies are: Baxter Vaccines, Berna Biotech, Biken, Chiron Vaccines, CSL Ltd, Crucell, Denka Seiken, GlaxoSmithKline Biologicals, ID Biomedical, Kaketsuken, Kitasato Institute, MedImmune, sanofi pasteur, Sanofi Pasteur MSD and Solvay Pharmaceuticals. The member companies - all involved in research, development and production of influenza vaccines, representing more than 90% of the world production - are putting together their efforts to ensure that in case of a pandemic, large quantities of a specific pandemic vaccine will be made available in the shortest period of time. Indeed, current worldwide production capacities are likely to be insufficient to meet the demand in case of a pandemic. The Scientific, Production and Research (SPR) subgroup of the task force is actively working on the technical issues for developing, licensing and producing a pandemic vaccine in close collaboration with national and international agencies, including the World Health Organization (WHO), the European Medicines Agency (EMEA) and the National Institute of Health (NIH) in the USA. Meanwhile the Policy, Practices and Communication (PPC) sub-group has published a series of articles in the scientific journal Vaccine, has initiated an analysis of influenza vaccine distribution throughout the world and a large health economic study on influenza vaccination in healthy adults 50-65 years old, which should support the public health and societal value of influenza vaccination. Finally the IVS international task force will shortly issue a position paper on the industry perspective on pandemic preparedness. www.iex.nl/forum/topic.asp?forum=228&... Uit de vogelgriepdraad: Update 24-01-2006. R&D for Avian/Pandemic Influenza Vaccines by IFPMA Influenza Supply International Task Force (IVS ITF) members.www.ifpma.org/pdf/avian_pandemic_infl... www.iex.nl/forum/topic.asp?forum=228&... En verder "een paar" linkjes m.b.t.( o.a malaria/TB) GAVI/NIH/Gates Foundation/IAVI/Aeras/etc.etc....een forum vol info:www.iex.nl/forum/topic.asp?forum=228&... www.iex.nl/forum/topic.asp?forum=228&... www.iex.nl/forum/topic.asp?forum=228&... www.iex.nl/forum/topic.asp?forum=228&... www.iex.nl/forum/topic.asp?forum=228&... www.iex.nl/forum/topic.asp?forum=228&... www.iex.nl/forum/topic.asp?forum=228&... www.iex.nl/forum/topic.asp?forum=228&... www.iex.nl/forum/topic.asp?forum=228&... www.iex.nl/forum/topic.asp?forum=228&... www.iex.nl/forum/topic.asp?forum=228&... www.iex.nl/forum/topic.asp?forum=228&...
hahahahaha FLOSZ!!!!!! SOEPER!!! Gaat het goed met je? Maar GAVI werd vlg mij in eerste instantie niet in verband gebracht met mijn posting van het bedrijfsbezoek... Japie
GREAT............. FLosz is ........ back ........ Doe je het wel een beetje rustig aan......... niet meteen alles uit de kast halen en VOORAL ...... HEEL zuinig op je zelf zijn. Er is maar een....... JIJ ....... zoals jij bent en heb je gezien op het forum willen we heel zuinig op zijn . Heel fijn weer te zien dat je de ruimte gevonden hebt om ook hier weer te willen zijn... Ian
Japies schreef:
hahahahaha FLOSZ!!!!!!
SOEPER!!! Gaat het goed met je?
Maar GAVI werd vlg mij in eerste instantie niet in verband gebracht met mijn posting van het bedrijfsbezoek...
Japie
Niet door mij in ieder geval. Maar het bij nader inzien..... Welcome back flosz. Heb je de zooi gezien op het forum? Als de kat van huis is, dansen de muizen op tafel. Gelukkig gaan we weer bergopwaards met ons gedrag ;)
Ik zet er even een stukje neer met het risico om door Flosz te worden gecorrigeerd. Hier druipt het Quinvaxem vanaf. Paris Presentation Introduces a New Supranational Bond Issuer: The International Finance Facility for Immunisation Expected Proceeds to Scale up GAVI Alliance, Boosting Vaccine Use, Improving Health Systems to Save Lives of Millions of Poorest Children Paris, 11 October 2006. The International Finance Facility for Immunisation (IFFIm), the World Bank, as IFFIm's treasury manager, and joint-lead managers Deutsche Bank and Goldman Sachs have embarked on a road show this week, stopping in five European cities to meet with potential investors to provide them with background information on IFFIm and its funding objectives. IFFIm is a new international development institution designed to accelerate the availability of funds to be used for health and immunisation programmes through the GAVI Alliance in 70 of the poorest countries around the world. “The creation of IFFIm provides investors with an opportunity to participate in the scaling up of a highly successful public-private collaboration that is focused on saving and improving the lives of the world’s youngest and most vulnerable citizens,” said Julian Lob-Levyt, Executive Secretary of the GAVI Alliance. “The new funds will enable GAVI to build on its successes, strengthening health systems in the poorest nations and expanding access to vaccines that would once have been considered out of reach.” According to the World Bank, IFFIm’s Treasury Manager, and subject to market conditions, IFFIm plans to launch the inaugural transaction in the US$ market in the coming weeks in a benchmark maturity and a size of US$750 million to US$1 billion, taking into account the institution’s financing needs for immunisation programmes in the next months and investor feedback. "IFFIm will enable us to do something to prevent the terrible burden of suffering on poor nations, while saving the lives of millions of children,” said Michèle Boccoz, Director of International Affairs for l’Institut Pasteur in Paris and member of the IFFIm Company Board. "In addition, we are being given the opportunity to demonstrate a new way of funding international development, addressing the seemingly intractable problems of poor nations with a tried and true model from the world of business.” The GAVI Alliance has reported significant advances in its first five years. A recent study in the Lancet, carried out by researchers at Harvard University, credits GAVI with successfully reversing a downward trend in the delivery of basic vaccines to children in the poorest nation.www.gavialliance.org/ Erik
Hoi Erik....linkje erbij:www.iex.nl/forum/topic.asp?forum=228&... gr. $1bn scheme to fund jabs for 5m children Larry Elliott Monday September 18, 2006 The Guardian Britain and seven other countries will launch up to $1bn (£530m) of bonds on financial markets next month in an attempt to provide the drugs to save the lives of 5 million children over the next five years, it was announced last night. Goldman Sachs and Deutsche Bank will coordinate the sale of the bonds on October 12, which will provide money for the Global Alliance for Vaccines and Immunisation. The public-private partnership will use the cash to bring forward programmes in poor countries in an attempt to hit the United Nations target of cutting infant mortality by two-thirds by 2015. Gordon Brown said Britain had been joined by seven other countries - France, Italy, Spain, Sweden, Norway, Brazil and South Africa - in floating the bonds on behalf of the World Bank. "This is about saving the lives of young infants who would otherwise die," the chancellor said. "It is utterly unacceptable that we have the vaccines, we have the drugs, we have the treatments and yet children who need them are denied them." Under the scheme, revenue from the bonds will pay to immunise millions of children far sooner than would otherwise have been possible. The money will be paid back to bondholders in the future. The chancellor said the initiative would eventually save 10 million lives and he was looking for more countries to join. Britain has been keen on selling bonds on capital markets to bring forward aid flows and the chancellor has been proposing an International Finance Facility to provide $50bn a year. Next month's bond launch of the IFF for immunisation will raise $4bn over the next four years, and is being seen by the UK as a dry run for a bigger facility. Treasury officials said the bonds would be AAA rated - the highest possible investment quality. ************** Bond to fund vaccines in poor countries takes to the road 02 Oct 2006 17:08:03 GMT Source: Reuters By Christina Fincher LONDON, Oct 2 (Reuters) - Six European countries plan to raise up to $1 billion in the international bond markets next week to buy life-saving vaccines for millions of children in the world's poorest countries. Bankers will kick off a series of roadshows to drum up investor interest in the scheme -- championed by British finance minister Gordon Brown -- first in the United States and then in Europe ahead of a likely launch on Oct 12. The scheme is a pilot for a wider bond financing project that could double rich countries' development aid to $100 billion a year but which has failed to get the backing of the United States. Funds raised will support immunisation projects against killer diseases such as measles and polio in 70 of the world's poorest countries. "The benefit of this concept is that it allows development bodies to front-load resources," said Christopher Egerton-Warburton, executive director at Goldman Sachs which is managing the sale along with Deutsche Bank. "With immunisation, there is clearly work that needs to be done today." The International Finance Facility for Immunisation will be managed by the World Bank and receive funding from Britain, France, Italy, Spain, Sweden, and Norway. Brazil and South Africa have pledged to join at a later date. Next week's offering is only the first leg of the initiative which aims to raise $4 billion in the bond markets over the next 10 years. SHAPE OF THINGS TO COME? Britain's Brown has long campaigned for the creation of a broader International Finance Facility to help meet the Millennium Development Goals on sharply reducing child mortality. But the plan -- which uses rich countries' aid pledges as collateral for cash in the present -- has run into opposition, particularly from the U.S. which does not want to make commitments under one administration that must be passed on to the next. Some lobby groups and aid agencies have also expressed concern that the scheme relies on future aid commitments and could pose problems further down the line. Bankers involved in the deal, nevertheless, are expecting a warm response. "Preliminary investor feedback has been very enthusiastic," said Doris Herrera-Pol, head of capital markets at the World Bank in Washington. Microsoft Chairman Bill Gates has also welcomed the bond initiative and his Gates Foundation has contributed $750 million to the vaccination project. Investor presentations will be held in New York on Tuesday and on the U.S. West Coast later this week, according to banking sources. The European leg of the roadshow will kick off in Switzerland on Monday, move to Frankfurt on Tuesday, Paris on Wednesday and London on Thursday. The bonds will have a top-notch triple A credit rating and are expected to carry a four- or five-year maturity. Final terms and conditions will depend on investor feedback and market conditions.
Hoi Flosz, ik wist het! Ik zal het speurwerk in het vervolg overlaten aan jouw en anderen. Trouwens bestaat er bij de GAVI ook een tender, of koopt deze in via de Unicef? mvg, Erik
Appointment Of Drug Company To GAVI Board Draws Criticism From NGOs Friday, May 27, 2011 The appointment of Dutch pharmaceutical company Crucell, recently acquired by Johnson & Johnson, to the board of the GAVI Alliance is "sparking concerns over conflicts of interest and demands for tougher competition to reduce prices," the Financial Times reports. With nearly 60 percent of Crucell's 2010 revenues coming from sales of its pentavalent vaccine to GAVI, the company's appointment "has triggered criticism from non-governmental organisations as GAVI seeks to raise $3.7bn at a meeting in London next month, against a backdrop of concerns that the agency has not done enough to improve value for money and lower the price it pays for vaccines." According to the article, "GAVI stressed it had a strict conflicts of interest policy, with board members 'recused' from discussions and without access to documents on matters where there was a direct conflict. ... All members of the board have conflicts, including UNICEF, which is the intermediary procuring nearly all the vaccines paid for by GAVI, the World Health Organisation, which receives funding to help its work, and countries including Rwanda and Ethiopia, which have received vaccine support" (Jack, 5/27).tinyurl.com/3vgtdrv
Volledig art. Conflict of interest fears over vaccine group By Andrew Jack in London Published: May 27 2011 00:23 | Last updated: May 27 2011 00:23 A vaccine company is set to join the board of the multilateral agency that provides it with most of its income, sparking concerns over conflicts of interest and demands for tougher competition to reduce prices. Crucell, based in the Netherlands and recently acquired by Johnson & Johnson, the US healthcare group, will in July take over as one of two pharmaceutical industry representatives on the board of the Global Alliance for Vaccines and Immunisations (Gavi), which last year channelled €584m ($825m) of donors’ funds to vaccination programmes in low-income countries. Its appointment has triggered criticism from non-governmental organisations as Gavi seeks to raise $3.7bn at a meeting in London next month, against a backdrop of concerns that the agency has not done enough to improve value for money and lower the price it pays for vaccines. Daniel Berman, deputy director of the access campaign for Médecins sans Frontières, the medical charity, said: “We think some conflicts are too big to manage. If you look at the agenda of the board meetings at Gavi, almost all issues impact Crucell’s bottom line.” Crucell received €170m – or nearly 60 per cent of its revenues – last year from Gavi for sales of its Quinvaxem paediatric pentavalent vaccination to protect children against diphtheria, pertussis, tetanus, Hib disease and hepatitis. It has agreed contracts for up to €800m in sales during the period 2007-12. Gavi, created at the start of the millennium, has helped save millions of lives by accelerating vaccination programmes through a partnership between rich and poor governments, UN agencies, charities and pharmaceutical companies. But an evaluation the board commissioned last year concluded one failing of Gavi was that it “could have done much more” to reduce prices, “with serious implications for country affordability and sustainability”. Both Crucell and GlaxoSmithKline, the UK drug company it is replacing on the board, have until recently refused to stimulate competition by allowing publication of the prices at which they sell vaccines to Unicef, which buys them on behalf of Gavi. One concern was that competition based purely on price risked jeopardising quality, highlighted by problems last year that forced a rival supplier, Shantha of India, to recall stocks ordered with Gavi money. Gavi stressed it had a strict conflicts of interest policy, with board members “recused” from discussions and without access to documents on matters where there was a direct conflict. The new chairman, Dagfinn Høybråten, has pledged much more scrutiny of governance and increased efforts to cut vaccine prices. All members of the board have conflicts, including Unicef, which is the intermediary procuring nearly all the vaccines paid for by Gavi, the World Health Organisation, which receives funding to help its work, and countries including Rwanda and Ethiopia, which have received vaccine support. Jon Pender, vice-president for government affairs at GSK, said: “The value of the private sector has been well accepted and well regarded. If you have not got a potential conflict you probably should not be at the table.” Crucell referred questions to J&J, which did not reply to requests to comment.tinyurl.com/3zsprsl
Die Ronald Ik ben weg (:->D) Nou, ik ook!!!!!!! Sinds UIT Crucell , porto keer 5-10-20 pick your choice. Voel me niet meer belazerd, want heb zelf de keuzes gemaakt........................ met 1 maar........... nooit meer , alle verhalen geloven!! Bij Crucell kloppen er TEVEEL verhalen niet, of niet meer. Had gewoon de chart voor 100% moeten volgen. Stelling: Binnen 5 jaar brengt J&J , CruSELL wederom , naar de beurs voor een faktor 5-10 of meer. Mij persoonlijk interesseert het niet meer, want de aandelen waarin ik zit , NA verkoop CruSELL, doen al faktor 8-10 . Dus geen omkijken meer. Mijn eigen fout: Don't ever believe management: LOOK AT THE CHARTS. See you where ever Mechelen, België; 30 mei 2011 - Galapagos NV (Euronext: GLPG) kondigt vandaag aan dat Dr Ronald Brus de Raad van Bestuur van Galapagos zal verlaten. Ronald Brus is President en Chief Executive Officer van Crucell. Dr Brus was lid van de Raad van Bestuur van Galapagos van 2000 tot de beursgang in mei 2005. Hij werd opnieuw bestuurslid in april 2010. In februari 2011 werd Crucell overgenomen door Johnson & Johnson. Het beleid van Johnson & Johnson schrijft voor dat Dr Brus geen lid mag zijn van een Raad van Bestuur. Om die reden heeft Dr Brus zich per 25 mei 2011 teruggetrokken uit de Raad van Bestuur van Galapagos. "We danken Ronald voor zijn bijdrage als Lid van de Raad van Bestuur", zegt Onno van de Stolpe, CEO van Galapagos. "Ronald is vanaf het begin bij Galapagos betrokken geweest. Zijn strategisch inzicht en zijn ervaring als CEO van een biotechbedrijf hebben ons veel geholpen. Wij wensen hem voor de toekomst het allerbeste binnen Johnson & Johnson." Over Galapagos Galapagos (Euronext: GLPG; OTC: GLPYY) is een middelgroot biotechnologiebedrijf. Het bedrijf is gespecialiseerd in het ontdekken en ontwikkelen van moleculen en antilichamen met nieuwe werkingsmechanismen. Galapagos heeft één van de grootste pijplijnen in de biotech met zeven programma's in de klinische fase en meer dan vijftig chemische molecuul programma's in onderzoek en preklinische ontwikkeling. Via risicodragende allianties met GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, Roche en Servier kan Galapagos mogelijk tot EUR2,5 miljard aan succesbetalingen ontvangen plus royalty's. Galapagos heeft meer dan 800 medewerkers in zeven landen, met haar hoofdkantoor in Mechelen, België. Meer info op www.glpg.com. CONTACT Galapagos NV Elizabeth Goodwin, Director Investor Relations Tel: +31 6 2291 6240 ir@glpg.com
Drugmakers cut vaccine prices for poorer nations Branded and generic shots offered at big discounts Price cuts should help GAVI narrow $3.7 bln funding gap The price GAVI pays for pentavalent vaccines, which protect against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b, will also be cut by the India-based firms Serum Institute and Panacea Biotec <PNCA.NS>. Serum, which had already cut its price to $1.75 a dose, said it would "continue to provide the most competitive pricing," while Panacea said it would cut its price by up to 15 percent. Crucell and Sanofi Pasteur said they would extend GAVI prices on their pentavalent vaccines to 16 countries who are moving on from GAVI support to begin buying shots themselves. tinyurl.com/6hnrmtz
UNICEF Supply Annual Report 2010 June 23, 2011 In 2010, UNICEF Supply procured 97.5 million doses of pentavalent vaccine, which combines five vaccines to protect against diphtheria, pertussis, tetanus, hepatitis B and haemophilus influenzae. In 2010, UNICEF Supply bought pentavalent vaccine at a record low price of $2.25 per dose compared to $3.60 for most of the vaccine procured in 2009. Accelerated demand for pentavalent has helped to bring down the price. The 5 in1 vaccine reduces the number of times children need to be immunised, and lowers costs for shipping and syringe disposal.www.unicef.org/publications/files/UNI... Serum Institute announces 60% cut in prices of pentavalent vaccine www.inewsone.com/2011/06/13/pune-firm...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
881,78
+0,30%
EUR/USD
1,0790
-0,20%
FTSE 100
7.952,62
+0,26%
Germany40^
18.505,40
+0,07%
Gold spot
2.234,24
0,00%
NY-Nasdaq Composite
16.379,46
-0,12%
Stijgers
Dalers